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Aims Due to a high burden of systemic cardiovascular events, current guidelines recommend the use of statins in all patients
with peripheral artery disease (PAD).We sought to study the impact of statin useon limb prognosis in patients with symp-
tomatic PAD enrolled in the international REACH registry.
Methods Statin usewas assessed at study enrolment, as well as a time-varying covariate. Rates of the primary adverse limb outcome
(worsening claudication/new episode of critical limb ischaemia, new percutaneous/surgical revascularization, or ampu-
tation) at 4 years and the composite of cardiovascular death/myocardial infarction/stroke were compared among
statin users vs. non-users.
Results A total of 5861 patients with symptomatic PAD were included. Statin use at baseline was 62.2%. Patients who were on
statins had a significantly lower risk of the primary adverse limb outcome at 4 years when compared with those who were
not taking statins [22.0 vs. 26.2%; hazard ratio (HR), 0.82; 95% confidence interval (CI), 0.72–0.92; P ¼ 0.0013]. Results
were similar when statin use was considered as a time-dependent variable (P ¼ 0.018) and on propensity analysis
(P, 0.0001). The composite of cardiovascular death/myocardial infarction/stroke was similarly reduced (HR, 0.83;
95% CI, 0.73–0.96; P ¼ 0.01).
Conclusion Among patients with PAD in the REACH registry, statin use was associated with an 18% lower rate of adverse limb
outcomes, including worsening symptoms, peripheral revascularization, and ischaemic amputations. These findings
suggest that statin therapy not only reduces the risk of adverse cardiovascular events, but also favourably affects limb
prognosis in patients with PAD.
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Introduction
Lower extremity peripheral artery disease (PAD) affects nearly one-
fifth of all adults older than 55 years of age, with increased prevalence
in high-risk subgroups such as those with diabetes, renal insufficiency,
and smoking.1– 4 Patients with PAD have high rates of systemic event
rates such as myocardial infarction, stroke, and death, with higher
rates in symptomatic patients.5 –12 These can be as high as five-fold
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for cardiovascular mortality and three-fold for all-cause mortality
after adjustment for known Framingham risk factors.5 In a pre-
specified subgroup analysis of the Heart Protection Study (HPS) in
patients with known PAD, simvastatin use was associated with a
20–25% reduction in major adverse cardiovascular events when
compared with placebo.8 Accordingly, current guidelines for second-
ary prevention and risk reduction in patients with PAD strongly rec-
ommend lipid-lowering therapy with a statin to achieve a goal
low-density lipoprotein (LDL) level of ≤100 mg/dL in low-risk
patients and ≤70 mg/dL in high-risk patients.13,14 However, patients
with PAD also have a high incidence of adverse limb outcomes. This
can be as a high as a 25% annual risk of limb amputation in patients
with advanced disease.15 The association between statin use and
limb outcomes in patients with PAD is unclear.
Since a randomized controlled trial would be unethical given the
known salutary effects of statins on cardiovascular outcomes, we
decided to investigate this hypothesis further in the large internation-
al Reduction of Atherothrombosis for Continued Health (REACH)
Registry.
Methods
Study population
Themethods of theREACHRegistry have beenpublished previously.16–20
Briefly, 69 055 patients at least 45 years old with ≥3 risk factors for ath-
erosclerosis and patients with established coronary, cerebrovascular, or
PAD were enrolled between 2003 and 2004. The multiple risk factors
category consisted of diabetes, diabetic nephropathy, symptomatic or
asymptomatic ankle-brachial index ≤0.9, asymptomatic carotid stenosis
of ≥70%, carotid intima media thickness at least two times that at adja-
cent sites, systolic blood pressure ≥150 mmHg despite treatment,
hypercholesterolaemia treated with medication, current smoking of
≥15 cigarettes per day, and age ≥65 years for men or ≥70 years for
women. These patients were assessed annually at years 1 through 4,
and follow-up was completed in 2008. For the purpose of this analysis,
we restricted the data set to patients with documented symptomatic
PAD who had complete 4-year follow-up information (Figure 1). Docu-
mented symptomatic PAD consisted of current intermittent claudication
with an ankle-brachial index of,0.9 and/or a historyof intermittent clau-
dication together with a previous intervention, such as angioplasty, stent-
ing, atherectomy, peripheral arterial bypass grafting, or other vascular
interventions, including amputations.
Ascertainment of exposure variables
Data relating to statin use were ascertained based on physicians’ report
on the standardized international case report form at each study visit. In-
formation regarding the use of other medications, systolic and diastolic
blood pressure, and fasting glucose and cholesterol levels was also
obtained at each visit.
Ascertainment of outcomes
The primary outcome of interest was worsening PAD, which was a com-
posite of worsening claudication/new episode of critical limb ischaemia
(CLI), new lower extremity percutaneous or surgical revascularization,
or amputation. Individual components of this composite endpoint
were also studied. Endpoints were not adjudicated, but based on phys-
ician reporting at the time of follow-up. Subsequent lower extremity
revascularization had to be chart-documented.
The keysystemic/secondaryoutcomewasacompositeof cardiovascu-
lar death, non-fatal myocardial infarction, or non-fatal stroke over 4 years.
Otherendpoints studied were all-cause mortality, cardiovascular mortal-
ity, non-fatal myocardial infarction, and non-fatal stroke (see Supplemen-
tary material online, Methods for definitions).16
Role of physician subspeciality
We compared statin non-usage rates by the subspeciality of the physician
enrolling a given patient into the REACH registry: general or internal
medicine/family practice vs. cardiology vs. angiology vs. vascular
surgery vs. others. Physician subspeciality was self-reported.
Statistical analysis
The mean (standard deviation) and percentages are reported for con-
tinuous and categorical variables, respectively. Cumulative incidence
rates were obtained using the Kaplan–Meier approach. Multivariate
Cox regression analyses were conducted, with time to adverse limb
events (worsening claudication/new episode of CLI, new percutaneous
or surgical revascularization, or amputation), and systemic events (car-
diovascular death, non-fatal myocardial infarction, or non-fatal stroke)
as the outcome variables, and statin use as the primary independent
variable. We also assessed extended Cox models where statin use was
Figure 1 CONSORT flow diagram of study participants.
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included as a time-varying covariate, which meant that statin use could
differ at any of the five visits (baseline, years 1–4). Hazard ratios (HRs)
and their 95% confidence intervals (CIs) were calculated. Other variables
included in these models have all been shown to be significant independ-
ent predictors of the primary systemic outcome at 4 years in a prior ana-
lysis.20 These include: gender, age, current smoker, history of diabetes,
aspirin use, body mass index ,20 (calculated as weight in kilograms
divided by height in metres squared), timing of ischaemic event (≤1 or
.1 year), polyvascular disease vs. single vascular disease, congestive
heart failure, atrial fibrillation/flutter, and Eastern Europe, Middle East,
or Japan vs. other regions. Geographic regions were collapsed into
higher (Eastern Europe and Middle East) and lower (Japan/Australia)
risk locations. Interaction terms for diabetes mellitus, smoking, gender,
and atherosclerosis in other distributions were individually tested.
Under conditions of competing risks, the Cox regression models can
produce misleading results,21 so a competing risk analysis was performed
using the %CIF macro in SAS.22 We compared the overall cumulative in-
cidence of adverse limb outcomes (adverse limb outcome before and
after cardiovascular death/myocardial infarction/stroke) stratified by
statin use. Differences in curves were tested using Gray’s23 test for equal-
ity of cumulative incidence functions.
Propensity analysis
To further account for significant differences in baseline characteristics
between statin-users and non-users, we conducted a propensity analysis.
Propensity scores for all patients were first estimated using a non-
parsimonious multivariable logistic regression model, with the depend-
ent variable of statin use at enrolment, and 15 baseline characteristics
(includingpresenceofCADandcerebrovascular disease)enteredas cov-
ariates. Propensity analysis was then conducted using inverse probability
of treatment weights (IPTW), wherein individuals are weighted by the
inverse probability of receiving the treatment that they actually received.
Toavoid bias fromvery largeweights, themean weightwascalculated and
utilized to normalize the weights, which were then introduced in a
weighted least squares regression model along with other predictor cov-
ariates. The IPTW method is inclusive of all subjects in a study; therefore,
no loss of sample occurs as in other conditioning methods, i.e. matching,
stratification.24,25
Missing values for covariates were not imputed. For the time-varying
analysis, a large number of patients did not have statin use information at
years 3 and 4 (values missing for 21.8% at year 3, and 32.1% at year 4).
For this analysis, imputations were performed as follows: if year 3 or
year 4 information was missing (either, not both), then the single available
valuewas assumed forbothyears. If informationwasmissing forbothyears,
the last available statin use information from year 2 was carried forward.
All statistical analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC, USA). All P-values were two-tailed, with statistical
significance set at 0.05. All CIs were calculated at the 95% level.
Results
A total of 5861 patients with established PAD were included, of
which 2492 (42.5%) had a history of or current intermittent claudica-
tion only (ABI value , 0.9 without prior revascularization), 3085
(52.6%) had undergone prior lower extremity arterial revasculariza-
tion (angioplasty/stenting/bypass graft), and 800 (13.6%) had under-
gone prior leg amputation at any level. Among these patients,
48.6% had concomitant coronary artery disease (CAD), 22.4% had
cerebrovascular disease, 58.7% had polyvascular disease, and 12.3%
had established disease in all three territories. Overall statin use in
this patient population was 62.2% (74.5% in patients with concomi-
tant CAD and in 64.0% patients with concomitant cerebrovascular
disease) (Figure 2). Approximately two-thirds of these patients
(65.0%) were enrolled by primary care or family practice physicians,
15.0% by vascular surgeons, 7.0% by cardiologists, 5.3% by angiolo-
gists, and 7.8% by others (Figure 3). Baseline characteristics of the
study population based on statin use are demonstrated in Table 1.
Patients who were not on statins at the time of enrolment were
more likely to be older, male, and have experienced a PAD event
(symptom/procedure) within the preceding year. Conversely,
patients who were on statins were more likely to have multiple
Figure 2 Proportion of patients on statins at enrolment.
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comorbidities including diabetes, hypercholesterolaemia, obesity,
heart failure, CAD, and polyvascular disease; they were also more
likely to be current smokers.
Statin use and adverse limb outcomes
A total of 1207 new adverse limb events occurred over 4 years
(incidence ¼ 23.6%), including 999 new revascularization proce-
dures and 222 new ischaemic amputations. On multivariate analysis,
the composite adverse limb outcome was lower in patients who
were on statins at study enrolment when compared with those
who were not on statins (22.0 vs. 26.2%; HR, 0.82; 95% CI, 0.72–
0.92; P ¼ 0.0013). The individual components of the primary
endpoint, including worsening claudication or new critical limb
ischaemia (14.7 vs. 18.2%; HR, 0.82; 95% CI, 0.70–0.95; P ¼
0.0087), new lower extremity percutaneous/surgical revasculariza-
tion (18.2 vs. 21.7%; HR, 0.83; 95% CI, 0.72–0.95; P ¼ 0.0079), and
new ischaemic amputation (3.8 vs. 5.6%; HR, 0.64; 95% CI,
0.48–0.86; P ¼ 0.0027) were all higher in patients who were not
on statins. Time-varying analysis and the propensity analysis demon-
strated similar results (Table 2). A separate analysis was performed
in all patients with PAD in the REACH registry, not just in those
with available 4-year data (7994 patients with available baseline
and statin use information). Results were quantitatively similar
(HR, 0.85, 95% CI 0.75–0.98; P ¼ 0.023). On competing risk ana-
lysis, the cumulative incidence of the adverse limb outcome re-
mained significantly lower in patients who were on statins at
study enrolment (21.1 vs. 25.1%; P ¼ 0.0007).
On subgroup analysis, overall results were similar in those with
stable claudication only at baseline vs. those with lower extremity
revascularization procedures or amputations. None of interaction
terms tested attained statistical significance (Figure 4).
Statin use and systemic events
Over a follow-up period of 4 years, patients who were on statins
demonstrated a 17% lower risk of the primary systemic endpoint
of cardiovascular death, non-fatal myocardial infarction, or non-fatal
stroke on multivariate analysis (19.6 vs. 20.3%; HR, 0.83; 95% CI,
0.73–0.96; P ¼ 0.01). Other endpoints including all-cause mortality
(17.3 vs. 19.7%; HR, 0.83; 95% CI, 0.72–0.96, P ¼ 0.014), cardio-
vascular mortality (11.4 vs. 12.4%; HR, 0.84; 95% CI, 0.70–1.00;
P ¼ 0.05), and non-fatal stroke (6.0% vs. 6.8%; HR, 0.74, 95% CI
0.57–0.95; P ¼ 0.016) were all similarly higher in patients who
were not on statins at study enrolment. No difference was noted in
the rates of non-fatal myocardial infarction (HR, 0.85; 95% CI, 0.63–
1.14; P ¼ 0.28) or non-cardiovascular mortality (HR, 0.83; 95% CI,
0.65–1.06; P ¼ 0.13). Time-varying Cox models and the propensity
analysis noted similar results (Table 2). Cumulative incidence curves
for theprimaryadverse limboutcomeand for thecompositeofcardio-
vascular death, non-fatal myocardial infarction, or non-fatal stroke are
demonstrated in Supplementary material online, Figures S1 and S2.
Discussion
The results of our analysis of 5861 patients with established symp-
tomatic PAD in the international REACH registry indicate that the
use of statins in these patients is low (62%). As has been reported
before,26 CAD remains an important modulator of statin use: more
than 50% of patients without CAD were not on statins. Our results
indicate that patients who are on statins have an 18% lower long-
term risk of adverse limb outcomes when compared with those
patients who were not on statins. Both lower extremity revasculari-
zation procedures and need for ischaemic amputations were
decreased in patients who were on statins. To our knowledge, this
Figure3 Proportion of patients on statins at enrolment based on enrolling investigator’s subspecialty.Also reportedare proportionsbased on the
presence of concomitant CAD or not. CAD indicates coronary artery disease.
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Table 1 Baseline characteristics of the study population
Characteristic On statins (n5 3643) Not on statins (n5 2218) P-value
Socio-demographic
Age (years) 68.2 (9.5) 70.0 (10.0) ,0.0001
Men 71.4 74.6 0.0084
Region ,0.0001
North America/Latin America/Western Europe/Asia 84.8 69.7
Eastern Europe/Middle East 9.7 11.7
Japan/Australia 5.5 18.8
Comorbidities
Diabetes mellitus 44.6 39.7 0.0002
Hypercholesterolaemia 94.3 15.6 ,0.0001
Hypertension 83.8 73.7 ,0.0001
Obesity (BMI ≥ 30 kg/m2) 24.8 16.7 ,0.0001
Current smoker 53.3 47.7 ,0.0001
Heart failure 17.3 12.0 ,0.0001
Atrial fibrillation 10.2 10.6 0.65
Extent of vascular disease
Coronary artery disease 58.2 32.7 ,0.0001
Cerebrovascular disease 23.1 21.3 0.11
Polyvascular disease 67.6 44.2 ,0.0001
PAD event within past year 38.1 46.1 ,0.0001
Baseline ABI value 0.72 (0.18) 0.70 (0.19) 0.01
Qualifying PAD diagnosis
ABI, 0.9 89.4 91.5 0.0089
Prior revascularization 54.0 50.4 0.0076
Prior amputation 13.2 14.3 0.23
Enrolling investigator speciality/subspeciality
Primary care/family practice 72.2 53.1 ,0.0001
Cardiology 8.9 3.9 ,0.0001
Angiologist 3.6 8.1 ,0.0001
Vascular surgeon 8.9 24.9 ,0.0001
Other 6.5 10.0 ,0.0001
Laboratory values
Serum creatinine (mg/dL) 1.1 (0.8) 1.1 (0.7) 0.74
Fasting blood glucose (mg/dL) 121.9 (45.6) 119.2 (48.5) 0.83
Fasting total cholesterol (mg/dL) 197.5 (57.2) 202.0 (44.9) 0.0042
Fasting triglycerides (mg/dL) 172.7 (102.3) 152.4 (96.1) ,0.0001
Medication history
Aspirin 66.3 51.2 ,0.0001
ACE inhibitor 49.5 33.9 ,0.0001
ARB 21.6 18.0 0.0009
b-Blocker 45.3 26.2 ,0.0001
Diuretic 47.2 33.8 ,0.0001
Calcium-channel blocker 38.3 35.3 0.022
Nitrate/other antianginal medication 26.7 17.0 ,0.0001
Other antihypertensive 10.1 8.4 0.029
NSAIDs 10.9 7.6 ,0.0001
Numbers represent mean (standarddeviation) forcontinuous variables, and % forbinaryorcategorical variables. P-values were obtained with Student’s t-test for continuousvariables,
and x2 test for categorical variables.
ABI, ankle brachial index; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug.
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is one of the largest cohort studies in stable outpatients with PAD,
and one of the first to demonstrate an association between statin
use and limb prognosis. Given the high morbidity and mortality asso-
ciated with limb procedures, especially amputations,27 our findings
are thus of potential public health importance. Also, consistent
with data from randomized controlled trials such as HPS,8 our
study indicates an 20% lower rate of systemic cardiovascular
events associated with statin use.
The benefit of statin therapy on adverse limb outcomes is not
clearly defined.1,28 Mohler et al.29 randomized 354 patients with
intermittent claudication to atorvastatin or placebo, and noted
improvements in pain-free walking distance at 12 months. Similar
functional improvements have been reported in other single-centre
observational studies.30 – 32 In a retrospective review of 1357
patients undergoing lower extremity revascularization procedures,
Ardati et al.10 reported that non-usage of both statin and aspirin
was associated with a 55% lower rate in the need for further inter-
ventions including ischaemic amputations at 6 months, although
the individual contribution of statin non-use was not reported. In
the HPS subanalysis, simvastatin use was associated with a 20%
lower rate in the need for non-coronary revascularization proce-
dures, including carotid procedures. No differences were noted in
rates of amputation.8 Thus, in addition to being one of the first
study to report on the association between statin use and adverse
limb outcomes, our study extends the statin–PAD association in
several important ways. Given the large sample size, we report an
associated lower rate not only in the composite adverse limb
outcome of worsening symptoms or development of critical limb is-
chaemia, need for lower extremity revascularizations, and ischaemic
amputations, but also in each of these outcomes individually. While
worsening claudication and need for revascularization procedures
can sometimes be subjective (i.e. patient and provider-dependent),
the requirement of an ischaemic amputation is a fairly objective
outcome. We also report that the beneficial associations of statins
on limb outcomes are apparent in patients across the full spectrum
of symptomatic PAD: from patients with intermittent claudication
alone to those who had undergone lower extremity revasculariza-
tions to those with prior amputations.
Another interesting observation in our registry is differences in
statin use based on enrolling physician subspeciality. Patients were
most likely to be on statins if enrolled by a cardiologist, and least
likely if enrolled by a vascular surgeon. This discrepancy was most
marked in patients without established CAD. Although differences
in the utilization of evidence-based therapies between cardiologists
and internal medicine or general practice physicians have been docu-
mented for patients with CAD,33,34 there are very few studies inves-
tigating the role of the physician subspeciality and secondary
prevention in patients with PAD.35 Although physician awareness is
likely part of the problem,2 further research is urgently needed to
explore reasons for differences in secondary prevention medication
use based on physician subspeciality.
One might wonder whether a unique form of unmeasured con-
founding known as ‘healthy user effect’ could be operational
here—the lower risk of adverse outcomes associated with statin
use may be a surrogate marker for overall healthy behaviour such
as healthy eating and regular exercise. However, this is unlikely for
the following reasons. Patients in the current study who were on
statins had more comorbidities and a higher severity of illness than
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Table 2 Adjusted multivariate hazard ratios for 4-year systemic and adverse limb outcomes in patients who were on
statins vs. those who were not on statins
Endpoint Multivariate adjusted model for
statinnon-useatbaseline(n 5 5861),
HR (95% CI); P-value
Multivariate adjusted model for
time-varying statin use (n5 5006),
HR (95% CI); P-value
IPTW weighteda multivariate
adjusted model (n5 5642),
HR (95% CI); P-value
Adverse limb outcomes
Worsening PADb 0.82 (0.72–0.92); P ¼ 0.0013 0.85 (0.75–0.97); P ¼ 0.018 0.79 (0.71–0.89); P, 0.0001
Worsening
claudication or new
CLI
0.82 (0.70–0.95); P ¼ 0.0087 0.84 (0.72–0.99); P ¼ 0.037 0.78 (0.68–0.90); P ¼ 0.0005
New revascularization
procedure
0.83 (0.72–0.95); P ¼ 0.0079 0.90 (0.77–1.04); P ¼ 0.14 0.79 (0.69–0.90); P ¼ 0.0003
New amputation 0.64 (0.48–0.86); P ¼ 0.0027 0.60 (0.44–0.82); P ¼ 0.0014 0.57 (0.43–0.74); P, 0.0001
Systemic outcomes
CV death/MI/stroke 0.83 (0.73–0.96); P ¼ 0.01 0.79 (0.67–0.93); P ¼ 0.0038 0.85 (0.75–0.96); P ¼ 0.0071
All-cause mortality 0.83 (0.72–0.96); P ¼ 0.014 0.79 (0.65–0.94); P ¼ 0.0098 0.96 (0.84–1.09); P ¼ 0.50
CV mortality 0.84 (0.70–1.00); P ¼ 0.05 0.78 (0.61–0.98); P ¼ 0.034 0.90 (0.77–1.06); P ¼ 0.21
Non-fatal MI 0.85 (0.63–1.14); P ¼ 0.28 0.80 (0.58–1.11); P ¼ 0.18 0.67 (0.52–0.87); P ¼ 0.002
Non-fatal stroke 0.74 (0.57–0.95); P ¼ 0.016 0.75 (0.57–0.97); P ¼ 0.029 0.73 (0.59–0.92); P ¼ 0.006
CI, confidence intervals; CLI, critical limb ischaemia; CV, cardiovascular; HR, hazard ratio; IPTW, inverse probability of treatment weights; MI, myocardial infarction; PAD, peripheral
artery disease.
aFor propensity analysis.
bWorsening claudication/new development of critical limb ischaemia, new percutaneous or surgical intervention, or amputation.
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statin non-users, arguing against a healthy user effect in the current
analysis. If anything, these differences would bias the results
towards the null, and the beneficial association with statin use may
be even larger. Secondly, we did not observe a significant difference
in non-cardiovascular mortality between statin users and non-users
in the current study. Finally, the impact of a ‘healthy user’ effect in
similar settings itself has been recently disputed.36
Other limitations of the REACH data are those inherent to regis-
tries such as selection bias and the presence of unmeasured confoun-
ders.37 The two groups of patients were also fairly dissimilar. We
attempted to mitigate this problem using advanced statistical
methods to the extent possible. Results were fairly concordant
between the threedifferent methodologies, including on the propen-
sity analysis. Medication use was assessed by patient self-report using
detailed questionnaires/case report forms without external valid-
ation. Although other measures such as pharmacy prescription
refills and electronic medication monitors can be more accurate,
patient self-report has been shown to be the most useful method
in the clinical setting;38 the use of questionnaires also has good cor-
relation with various electronic measures.39 Information regarding
dose, potency of statin used, and side effects and contraindications
to their usewas also not available. Finally, this analysis is unable to sep-
arate statin non-usagedue tophysiciannon-prescription from patient
non-adherence. The former is a more surmountable problem and
may be alleviated by systems-based interventions, as have been insti-
tuted for acute myocardial infarction and heart failure.40
Conclusion
Our analysis of a large international cohort of patients with estab-
lished PAD indicates that the use of statins remains suboptimal, espe-
cially in patients without coexisting CAD. Patients who were taking
statins had a significantly lower risk of adverse limb and systemic car-
diovascular outcomes at 4 years. It is imperative to identify barriers to
patient and physician compliance with statin use across the entire
spectrum of PAD patients. In addition, future research should focus
on identifying a possible dose–response relationship between
statin use and limb outcomes, and also whether different LDL chol-
esterol targets may be necessary to prevent progressive PAD vs. pro-
gressive cardiovascular outcomes in these patients.
Figure4 Subgroup analysis of the effect of statin use on the composite adverse limb outcome at 4 years. CI, confidence intervals; HR, hazard ratio.
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Optical coherence tomography images of iliac artery
fibromuscular dysplasia
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A 47-year-old woman with a history of hyperten-
sion and cerebral infarction presented with inter-
mittent claudication. No pulse was palpable in the
bi-lateral dorsalis pedis, and peripheral arterial
disease was suspected. The ankle-brachial index
was 0.83 in the right leg and 0.76 in the left.
Duplex sonography revealed severe stenosis in
the bilateral external iliac artery (EIA) and renal
artery. The EIA had the characteristic ‘string of
beads’ appearance in angiography (Panel A),
which was diagnosed as fibromuscular dysplasia
(FMD). Endovascular therapy was performed for
the EIA. There was a 30 mmHg pressure gradient
in the FMD lesion. Optical coherence tomography (OCT) images revealed shrinkage of the media and mild thickness in the intima (Panels B
and C), while three-dimensional OCT images showed a ‘haustra coli’-like appearance (Panel D). After balloon angioplasty, the vessel was
well dilated and claudication disappeared.
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